Scientific founders of seed companies often do not have the expertise, capabilities, and/or time for all the critical aspects in turning science into a business. Their primary focus, as leading experts, should be on their key strength – advancing science.

However, the harsh reality of today’s economic environment is that science alone is not enough for funding. Venture firms need to see science aligned with a commercially viable strategic vision and the operational capacity to execute.

Ex³ helps startups that are struggling with operational decisions – from hiring C-suite executives, to figuring out a company’s IT and administrative needs, Ex³ accelerates companies from Seed funding to the next round of funding through IPO.

At Ex³, we understand the unique challenges faced by early-stage biotech companies. We have worked with numerous startups, witnessing journeys from conception to commercialization. Our extensive knowledge and hands-on approach offer solutions tailored to your needs, ensuring success at every step of the way.

Ex³ by Portal Innovations is led by Ritu Shah, an industry veteran with an impressive 25+ years of experience at Shire, AveXis, Levo Therapeutics, and Pyxis Oncology. Joined by Karol Sokolowski, bringing 10+ years of translational biomedical R&D, strategic consulting, and clinical experience, our team brings unparalleled expertise and insights to help your biotech thrive.

Please reach out to karol.sokolowski@portalinnovations.com.